MDGLMadrigal Pharmaceuticals, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+10% of shares).
Rangebound, no clear trend. Oversold (RSI 25). Price is −14% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MDGL is trading
Madrigal Pharmaceuticals, Inc. is −1.9% over the past year while the S&P 500 is +16%: 18 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −14%
vs 200-day average · a clear downtrend
- RSI (14)
- 25
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 28%
Below its 52-week high
Details›
- Last close2026-10-23
- $433.63
- 1 monthS&P 500 −0.94%
- −16%
- 1 yearS&P 500 +16%
- −1.9%
- 5 yearsS&P 500 +86%
- +433%
- vs 50-day average$506.75
- −14%
- 52-week high
- $602.83
- 52-week low
- $412.35
- Annualised volatility
- 52%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $2.1M
| Year | Return |
|---|---|
| 2026 (year to date) | −26% |
| 2025 | +89% |
| 2024 | +33% |
| 2023 | −20% |
| 2022 | +243% |
| 2021 | −24% |
| 2020 | +22% |
| 2019 | −19% |
| 2018 | +23% |
| 2017 | +516% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +1.8% |
| Feb | 10 | 7 of 10 | +6.1% |
| Mar | 10 | 3 of 10 | −1.3% |
| Apr | 10 | 5 of 10 | +0.66% |
| May | 10 | 3 of 10 | +11% |
| Jun | 10 | 7 of 10 | +3.7% |
| Jul | 11 | 2 of 11 | −8.0% |
| Aug | 11 | 7 of 11 | +8.8% |
| Sep | 11 | 4 of 11 | +11% |
| Oct | 11 | 6 of 11 | +3.7% |
| Nov | 10 | 6 of 10 | +9.9% |
| Dec | 10 | 4 of 10 | +37% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.